GlassScriptPhysician profile
Chelsea Shakes
NPI 1104653450
$809.63
in general payments reported to CMS, 2019-2025
15 companies · $810 in 2025
The $810 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $121.59 | 2025 | |
| Glaxosmithkline, LLC. | $107.30 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Grifols USA, LLC | $90.69 | 2025 | Prolastin-C Liquid |
| Amgen INC. | $89.72 | 2025 | Tezspire |
| Ani Pharmaceuticals, INC. | $64.91 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $53.41 | 2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $51.45 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $49.72 | 2025 | Airsupra |
| Insmed, INC. | $38.82 | 2025 | Brinsupri, Arikayce |
| Verona Pharma, INC. | $32.66 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $27.96 | 2025 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $27.78 | 2025 | Opsynvi |
| Baxter Healthcare | $19.13 | 2025 | Hillrom - Monarch Airway Clearance System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.29 | 2025 | Jascayd |
| Bayer Healthcare Pharmaceuticals INC. | $16.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Shakes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.